リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.

BAXTER Mike MORIMOTO Yukiko TAMIWA Masami HATTORI Masakatsu PENG Xuejun Victor LUBWAMA Robert MAEGAWA Hiroshi 00209363 0000-0002-4611-8149 滋賀医科大学

2020.05.22

概要

Introduction:
The effectiveness of basal insulin (BI) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in providing glycemic control in patients with type 2 diabetes (T2D) in Japanese routine practice is not well known. This real-world observational study evaluated the probability of achieving glycemic control in Japanese patients with T2D uncontrolled by oral antidiabetic drugs (OADs) who initiated BI or GLP-1 RA therapy.
Methods:
Patients with T2D aged ≥ 18 years initiating BI or GLP-1 RA therapy following treatment with OADs were selected from real-world data (RWD) retrieved from a large electronic medical record database in Japan, using data from 01 January 2010 to 30 June 2019. Patients were required to have glycated hemoglobin (HbA1c) ≥ 7% within 90 days prior to the first prescription of BI or GLP-1 RA. The probability of reaching first HbA1c < 7% was assessed over a 24-month period in cohorts of patients who initiated BI (n = 3477) or GLP-1 RA (n = 780) and in subcohorts by number of OADs at baseline (1, 2, or ≥ 3), HbA1c at baseline (≥ 7 to < 8%, ≥ 8 to < 9%, or ≥ 9%), and age (< 65 or ≥ 65 years).
Results:
Mean (standard deviation) baseline HbA1c was 9.4% (1.8%) and 8.8% (1.4%) in patients initiating BI or GLP-1 RA therapy, respectively. The cumulative probability of achieving glycemic control was 50.1% with BI and 60.3% with GLP-1 RA therapy, respectively, at 12 months, and 60.8% and 66.6%, respectively, at 24 months. Quarterly (3-month intervals) conditional probabilities of achieving glycemic control decreased over time and were < 10% after 12 months. Patients with more OADs or higher HbA1c at baseline had a lower probability of achieving glycemic control.
Conclusion:
Among Japanese patients with T2D who initiated BI or GLP-1 RA therapy after treatment with OADs, the probability of reaching first glycemic control diminished over time. Further therapy intensification is warranted in patients who do not achieve glycemic control within 6-12 months with BI or GLP-1 RA, particularly those with high HbA1c or taking multiple OADs.

論文の公開元へ

この論文で使われている画像

関連論文

関連論文をもっと見る

参考文献

1.

Kahn SE, Cooper ME, Del PS. Pathophysiology and

treatment of type 2 diabetes: perspectives on the

past, present, and future. Lancet. 2014;383:

1068–83.

2.

Saisho Y. b-cell dysfunction: its critical role in prevention and management of type 2 diabetes. World

J Diabetes. 2015;6:109–24.

3.

Ohkubo Y, Kishikawa H, Araki E, et al. Intensive

insulin therapy prevents the progression of diabetic

microvascular complications in Japanese patients

with non-insulin-dependent diabetes mellitus: a

randomized prospective 6-year study. Diabetes Res

Clin Pract. 1995;28:103–17.

4.

[No authors listed]. Intensive blood-glucose control

with sulphonylureas or insulin compared with

conventional treatment and risk of complications

in patients with type 2 diabetes (UKPDS 33). UK

Prospective Diabetes Study (UKPDS) Group. Lancet.

1998;352:837–53.

5.

Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A

consensus report by the American Diabetes Association (ADA) and the European Association for the

Study of Diabetes (EASD). Diabetes Care. 2018;41:

2669–701.

6.

Haneda M, Noda M, Origasa H, et al. Japanese

clinical practice guideline for diabetes 2016. Diabetol Int. 2018;9:1–45.

7.

American Diabetes Association. Standards of medical care in diabetes–2020. Diabetes Care.

2020;43(Suppl 1):S1–S212.

Data Availability. These analyses were

conducted on medical records data provided

under a commercial license, which the authors

are unable to share.

Open Access. This article is licensed under a

Creative

Commons

Attribution-NonCommercial 4.0 International License, which

permits any non-commercial use, sharing,

adaptation, distribution and reproduction in

any medium or format, as long as you give

appropriate credit to the original author(s) and

Diabetes Ther

8.

Levin PA, Nguyen H, Wittbrodt ET, Kim SC. Glucagon-like peptide-1 receptor agonists: a systematic

review of comparative effectiveness research. Diabetes Metab Syndr Obes. 2017;10:123–39.

9.

Madenidou AV, Paschos P, Karagiannis T, et al.

Comparative benefits and harms of basal insulin

analogues for type 2 diabetes: a systematic review

and network meta-analysis. Ann Intern Med.

2018;169:165–74.

10. Porcellati F, Lin J, Lucidi P, Bolli GB, Fanelli CG.

Impact of patient and treatment characteristics on

glycemic control and hypoglycemia in patients

with type 2 diabetes initiated to insulin glargine or

NPH: a post hoc, pooled, patient-level analysis of 6

randomized controlled trials. Medicine (Baltimore).

2017;96:e6022.

11. Singh S, Wright EE Jr, Kwan AY, et al. Glucagon-like

peptide-1 receptor agonists compared with basal

insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes

Obes Metab. 2017;19:228–38.

12. Blonde L, Meneghini L, Peng XV, et al. Probability

of achieving glycemic control with basal insulin in

patients with type 2 diabetes in real-world practice

in the USA. Diabetes Ther. 2018;9:1347–58.

13. Peng XV, Blonde L, Shepherd L, Lubwama R, Ji L,

McCrimmon RJ. A real-world retrospective study

evaluating glycaemic control with glucagon-like

peptide-1 receptor agonists or basal insulin in type

2 diabetes in the UK. Diabetologia. 2019;62(Suppl

1):864.

14. STROBE. STrengthening the Reporting of OBservational studies in Epidemiology 2014. Available

from:

https://www.strobe-statement.org/index.

php?id=strobe-home. Accessed 6 Nov 2019.

15. Kobayashi M, Tsukube S, Ikeda Y, Shuto Y. Safety

and efficacy of combination therapy with insulin

glargine and oral hypoglycaemic agents including

DPP-4 inhibitors in Japanese T2DM patients:

ALOHA 2 study, a post-marketing surveillance for

LantusÒ. J Diabetes Mellitus. 2014;4:273–89.

16. Satoh J, Andersen M, Bekker Hansen B, et al. Clinical inertia in basal insulin-treated patients with

type 2 diabetes—results from a retrospective database study in Japan (JDDM 43). PLoS ONE. 2018;13:

e0198160.

17. Ishii H, Iwamoto Y, Tajima N. An exploration of

barriers to insulin initiation for physicians in Japan:

findings from the Diabetes Attitudes, Wishes And

Needs (DAWN) JAPAN study. PLoS ONE. 2012;7:

e36361.

18. Morita Y, Murayama H, Odawara M, Bauer M.

Treatment patterns of drug-naive patients with type

2 diabetes mellitus: a retrospective cohort study

using a Japanese hospital database. Diabetol Metab

Syndr. 2019;11:90.

19. Terauchi Y, Koyama M, Cheng X, et al. Glycaemic

control and hypoglycaemia with insulin glargine

300 U/mL compared with glargine 100 U/mL in

Japanese adults with type 2 diabetes using basal

insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including

6-month extension). Diabetes Metab. 2017;43:

446–52.

20. Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC,

Park S. Insulin degludec compared with insulin

glargine in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, panAsian, treat-to-target trial. J Diabetes Investig.

2013;4:605–12.

21. Araki E, Inagaki N, Tanizawa Y, Oura T, Takeuchi M,

Imaoka T. Efficacy and safety of once-weekly

dulaglutide in combination with sulphonylurea

and/or biguanide compared with once-daily insulin

glargine in Japanese patients with type 2 diabetes: a

randomized, open-label, phase III, non-inferiority

study. Diabetes Obes Metab. 2015;17:994–1002.

22. Inagaki N, Ueki K, Yamamura A, Saito H, Imaoka T.

Long-term safety and efficacy of exenatide twice

daily in Japanese patients with suboptimally controlled type 2 diabetes. J Diabetes Investig. 2011;2:

448–56.

23. Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T.

Efficacy and safety profile of exenatide once weekly

compared with insulin once daily in Japanese

patients with type 2 diabetes treated with oral

antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter,

noninferiority study. Clin Ther. 2012;34:1892–908.

24. Kaku K, Kiyosue A, Ono Y, et al. Liraglutide is

effective and well tolerated in combination with an

oral antidiabetic drug in Japanese patients with

type 2 diabetes: a randomized, 52-week, open-label,

parallel-group trial. J Diabetes Investig. 2016;7:

76–84.

25. Kaku K, Yamada Y, Watada H, et al. Safety and

efficacy of once-weekly semaglutide vs additional

oral antidiabetic drugs in Japanese people with

inadequately controlled type 2 diabetes: a randomized trial. Diabetes Obes Metab. 2018;20:

1202–12.

Diabetes Ther

26. Seino Y, Terauchi Y, Wang X, Watanabe D, Niemoeller E, Study Investigators. Safety, tolerability

and efficacy of lixisenatide as monotherapy in

Japanese patients with type 2 diabetes mellitus: an

open-label, multicenter study. J Diabetes Investig.

2018;9:108–18.

27. Edelman SV, Polonsky WH. Type 2 diabetes in the

real world: the elusive nature of glycemic control.

Diabetes Care. 2017;40:1425–32.

...

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る